Can a single infusion rewrite the genetic code behind wilson disease?

NCT ID NCT07748403

First seen Aug 05, 2026 · Last updated Aug 12, 2026 · Updated 3 times

Summary

This trial tests an experimental therapy called PM577a, which uses prime editing to correct a common genetic mutation that causes Wilson disease. The treatment is given as a single intravenous infusion and aims to restore the liver's ability to remove excess copper. The study includes adults and adolescents with Wilson disease who have at least one copy of the p.H1069Q mutation. Researchers will monitor safety, how the body responds, and whether copper metabolism improves.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
PM577a, an investigational prime editing therapy designed to correct the p.H1069Q mutation in the ATP7B gene
What this could lead to
If successful, this could lead to a one-time treatment that corrects the genetic cause of Wilson disease, potentially allowing patients to stop lifelong copper-removing medications.
What could go wrong
This is an early-stage, first-in-human trial, so safety and effectiveness are unproven. The editing may not work in all cells, and there are risks of immune reactions or unintended genetic changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WILSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • New Zealand Clinical Research (NZCR)

    Grafton, Auckland, 1010, New Zealand

More trials for these conditions

Other studies related to the condition(s) this trial covers.